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Abstract 
The complexation of the Pt-based anti-cancer drug oxaliplatin (OxPt) with biological ligands 
other than DNA is believed to be a major cellular sink for the drug reducing its therapeutic 
potential and acting as a potential cause of toxicity.  In this paper, an in vitro study on 
hepatocellular carcinoma HepG2 cells suggests that the naturally abundant cytoplasmic 
dipeptide ligand β-alanyl-L-histidine dipeptide (carnosine) may inhibit the cytotoxic action of 
OxPt most likely through the formation of complexes that are less cytotoxic than OxPt alone.  
Evidence is provided to suggest that pre-exposure of HepG2 cells to elevated levels of 
carnosine appears to have a lasting effect on reducing the cytotoxicity of OxPt even after the 
removal of the carnosine.  This effect, however, is shown to be under kinetic control as its 
magnitude was shown not to vary significantly with the level of carnosine exposure within 
the concentration range used in this study.  Various mass spectrometry techniques employing 
electrospray ionization and chip nanospray were employed to study the interaction of 
oxaliplatin with carnosine as well as two of its derivatives being β-alanyl-N-methylhistidine 
(anserine) and N-Acetylcarnosine (NAC).  Evidence of complexation between OxPt and each 
of the three ligands examined is presented.  Most species observed were unambiguously 
assigned and compared to their theoretical isotopic patterns.  Common fragmentation 
products due to the collisionally-activated protonated complexes of each of the ligands 
examined with OxPt, [M + OxPt + H]+ where M= carnosine, anserine or NAC were reported.  
Density functional calculations at B3LYP/LANL2DZ were used to obtain structural 
information and relative free energies of different isomers of the observed precursor 
[Carnosine + OxPt + H]+ both in the gas phase and in solution as well as to probe its 
fragmentation, highlighting plausible fragmentation mechanisms that account for all the 
experimental results.   
Data are presented to show several binding modes between electron rich sites such as N and 
O centers of carnosine and the Pt metal of OxPt.  Calculations were also employed to obtain 
proton affinities and free energies of key reactions. The proton affinities of carnosine, 
Anserine and NAC at 298 K were calculated to be 254.4, 255.9 and 250.2 kcal mol-1  
respectively.  To the best of our knowledge the proton affinities of anserine and N-acetyl-
carnosine are the first reported values in the literature.   
Introduction 
 
Oxaliplatin (OxPt) is a third generation chemotherapeutic drug used in the treatment of 
colorectal cancer and cisplatin resistant cancers, [1-13] it was developed to overcome the 
nephrotoxicity of cisplatin and myelosuppression with carboplatin treatment. [14] Oxaliplatin 
has a broader range of activity than cisplatin and increased cytotoxicity over cis and 
carboplatin due to increased inhibition of DNA synthesis and greater efficiency in DNA 
repair. [13, 15, 16] The amine groups of cisplatin are replaced by diaminocyclohexane (dach) 
to form [Pt(dach)oxalate], oxaliplatin. The dach ligand is not recognised by mismatch repair 
complexes, which may explain its effectiveness in the treatment of cisplatin and carboplatin 
resistant cancers. [15] 
The transport and interactions of oxaliplatin within cells is still not fully understood 
however,the simplistic route from blood to nuclear DNA involves the passive diffusion of 
oxaliplatin into the cell from the extracellular fluid where the Cl- concentration is high (> 100 
mM) into the cytoplasm, where the Cl- concentration is low (4-20 mM). [17] The low Cl- 
concentration in the cytoplasm results in the solvation of oxaliplatin, to its active forms 
[Pt(OH2)Cl(dach)]+ and [Pt(OH2)2(dach)]2+[11,13], shown in Figure 1 and can interact with a 
plethora of non-DNA ligands. Based on previous work by Zayed et. al.[18] we can assume 
that the majority of the administered drug is found in the cell cytosol.  It is thought that the 
most likely sites for oxaliplatin interaction are the thiol groups of intercellular peptides and 
proteins.  Recent studies have shown that the activated form of oxaliplatin forms very stable 
complexes with glutathione, being the most abundant low molecular weight thiol containing 
molecule in human cells. [19-21] However, work by this group [21, 22] and elsewhere [22, 
23] suggests that Pt binding to intercellular peptides through their terminal amino nitrogen 
atoms and carbonyl oxygen atoms are possible and energetically competitive to sulphur 
attachment.  This in combination with the large excess of these binding sites over those of 
sulphur raises the possibility of Pt adduction to non-thiol containing ligands in the proteome.  
All such non-DNA interactions are responsible for chemo-resistance and many of the side 
effects; including sensory-motor neuropathy, myelosuppression, gastrointestinal toxicity, 
idiosyncratic and hypersensitivity reactions. [24]   
The endogenous dipeptide L-carnosine (β-alanyl-L-histidine) was discovered by Gulewitsch 
and Amiradzibi [25] from muscle tissue extracts in 1900 [26, 27] and is found in several 
organs including the brain (olfactory bulb and hippocampus) [28], cardiac muscle, kidney and 
stomach.[29, 30]  In the skeletal muscle and nerve cells it is found at concentrations of up to 
20 mM.[31, 32]  Since its discovery there have been many investigations into its biological 
function and it is now known that carnosine acts as an anti-oxidant, scavenger of free radicals 
and active oxygen species [30], as a biological buffer, a source for histidine, an immuno-
stimulant and transition metal ion chelator, especially for Zn2+ and Cu2+ [33] and heavy 
metals. [34]  The ability of carnosine to bind Zn2+ helps modulate neuronal excitability by 
preventing the Zn2+ inhibition of neurotransmitter receptors. [35] Carnosine is also effective 
in the prevention and partial reversal of cataracts [36] and in the treatment of Wilsons disease 
[37] and Alzheimers due to its metal chelating and free radical scavenging ability and also 
acting as a β-amyloid toxicity inhibitor. [35, 38] It has also been shown that carnosine acts as 
a neuroprotector [39, 40] and can retard tumour growth in mouse models. [41]  More recently 
it has been reported that carnosine can prevent cell proliferation in colon cancer cells. [47, 
48]  The related dipeptides N-acetlycarnosine and anserine share many of the beneficial 
characteristics of carnosine. The N-acetyled form of carnosine, N-acetyl-carnosine has been 
shown to be effective in the treatment of stomach ulcers [42] and similarly to carnosine has 
been used in the treatment of cataracts. [43, 44] Anserine on the other hand, acts a chelator 
for copper and as an antioxidant as well as enhances the anti-tumour activity of doxorubicin. 
[45] Due to its presence in high abundance in the cytosolic fractions of cells [30] and its 
ability to scavenge transition metal elements we believe that the interactions between 
carnosine and oxaliplatin are of important scientific value.  The investigation of the 
coordination chemistry of carnosine and oxaliplatin may provide new understanding in the 
mechanism of the cellular response to these drugs. Given that there are 1-5 Pt adducts per 106 
nucleotides in patient white blood cells which represents approximately 10% of the total 
administered drug. [18] Assuming all nuclear Pt is bound to DNA, representing 
approximately 105 Pt atoms per cell, the majority of the administered drug is available to bind 
to other ligands such as proteins and peptides within the cell. With a large concentration of 
proteins per cell,  approximately 106-107, [46] many with multiple binding sites, the potential 
for a wide range of Pt adducts to exist within the cell rather than specific Pt targets is a 
possible scenario.  The interactions of carnosine and the related dipeptides anserine and N-
acetylcarnosine with Oxaliplatin are therefore of great interest.  By using a simple highly 
abundant dipeptide, such as carnosine to act as a simplified model of the broader Pt-
meallome, we present detailed structural analysis of carnosine and the hydrolysed forms of 
oxaliplatin.  
Instrumentation 
An LTQ linear ion trap mass spectrometer with an electrospray source and a high resolution 
Q-Exactive Fourier transform mass spectrometer (Thermo Electron, San Jose, CA, USA) 
were used. Both instruments were calibrated using Ultramark® 1621, caffeine and Met-Arg-
Phe-Ala (MFRA) in accordance with the manufacturer’s recommendations. The Q-Exactive 
was equipped with a Tri Versa NanoMate ESI chip nanospray (Advion, New York, USA). 
For the LTQ Resolving powers achieved were in the order of 1500 while the upper 
instrumental error limit in measurements was 0.2 m/z units. The LTQ auto-tune routine was 
used to obtain lens, quadrupole and octapole voltages for maximum transmission of the ions 
of interest. Helium gas, admitted into the ion trap at a maintained pressure of approximately 
10-3Torr, was used as the buffer gas to improve the trapping efficiency andas the collision gas 
for collision-induced dissociation (CID) experiments performed here at 15 eV in the lab 
frame. Experiments designed to elucidate ion structures or fragmentation pathways on the 
LTQ were performed as follows: the ion of interest was selected then collisionally activated 
by setting the activation amplitude at 25–35% of the maximum voltage available (determined 
empirically), and the activation Q setting (used to adjust the frequency of the RF excitation 
voltage) was set at 0.25 units. Sample solutions were continuously infused at a flow rate of 5 
µl min-1 into the pneumatically assisted electrospray probe using dry nitrogen as the 
nebulising gas. Auxiliary and sheath gases were tuned daily for maximum signal 
transmission.  Two tandem quadrupole mass spectrometers, An Acquity TQ and A XEVO 
TQ (Waters, MA, USA) both equipped with electrospray ionisation interface were also used 
in this work.  Both triple quadrupoles were operated in positive ion mode, with typical values 
of cone, capillary and extractor voltages set to 30, 2500, and 3 respectively. The desolvation 
gas was usually set at a flow of 250 L h−1 and a temperature of 150 ºC.  Argon was used as 
the collision gas at a typical flow rate of 0.15 ml min-1. Tandem mass spectra were obtained 
at collision energies in the range 5-25 eV in the lab frame having both Q1 and Q3 operated at 
unit resolution with typical a dwell time of 25 millisecond per transition. 
 
Reagents 
Carnosine, Anserine, HPLC-grade water and methanol were all purchased from Sigma-
Aldrich, UK. N-Acetyl carnosine was purchased from Nanjing Gemsen international, China 
while oxaliplatin was obtained from Sanofi-Synthelabo Limited (Guildford, UK). 
 
In Vitro cell viability assays  
To determine the in vitro effect of carnosine, the hepatocellular carcinoma cell line HepG2 
was exposed to varying concentrations of OxPt, as well as several solution mixtures of OxPt 
and carnosine. The viability of HepG2 was assessed through MTT assay, which utilizes the 
conversion of the tetrazolium salt MTT (dimethylthiazol diphenyl tetrazolium bromide 
purchased from Serva, Germany) to formazan by dehydrogenase enzymes in living cells. [49] 
In brief, cells were cultured in 96-well plate (30,000 cells/well) at 37 ºC humidified with 5% 
CO2 in DMEM (Dulbecco’s Modified Eagle Medium) supplemented with 10% FBS (Fetal 
bovine serum) and 5% Penicillin-Streptomycin mixture (Lonza, Switzerland). Cell counting 
was performed using Countess® Automated cell counter (Invitrogen). Solutions of OxPt at 8, 
12, 16, 20, 24 and 28 μg ml-1, as well as solution mixtures at varying molar ratios of 
carnosine at a fixed OxPt concentration of 24 μg ml-1 were made in the culture media. Each 
of the sample solutions made was incubated with the HepG2 cells for 24 hrs, wells containing 
cells treated only with media served as controls. After incubation the media was discarded, 20 
µl MTT (5 mg/ml) and 100 µl fresh media were added to each well and incubated for 3 
hours, all media was then discarded, and the purple formazan crystals formed were 
solubilized via the addition of 100 µl DMSO (Sigma-Aldrich, USA). The absorbance of each 
well was measured at 595 nm using a microplate reader FLUOstar OPTIMA (BMG LabTech, 
Germany).  Cell viability was determined by calculating the absorbance of the test wells as a 
percentage of the control wells. 
Results and discussion    
HepG2 cells showed decreased viability with exposure to increased concentrations of OxPt as 
shown in Figure 1. The most significant changes in cell viability were observed at exposure 
to OxPt concentrations of 16 μg ml-1 and greater as indicated by P values < 0.00001.  To 
examine the in vitro effect of carnosine on OxPt cytotoxicity, several solutions were prepared 
at a fixed OxPt concentration of 24 μg ml-1 while varying the molar equivalent of carnosine.  
While the choice of OxPt concentration in these experiments was arbitrary, a value was 
chosen that corresponds to relatively low cell viability in order to easily observe the effects of 
subsequent addition of carnosine.  It is also important to note that the OxPt concentration 
value chosen for these set of experiments was one that brought the most statistically 
significant decrease in the viability of the treated HepG2 cells as indicated by P values < 
0.00001 (see Figure 1).  The results of these experiments is shown in Figure 2 which points to 
a positive correlation between cell viability and increasing molar equivalence of canosine 
relative to OxPt.  These differences were much less pronounced past the initial incremental 
addition of carnosine where a significant increase in cell viability was shown due to the 
exposure of a 1:1 molar ratio of carnosine to Oxpt relative to cells only exposed to OxPt at 
the same concentration and for the same incubation time.  This was shown to be statistically 
significant with P value < 0.00001 at all non-zero molar ratios of carnosine to OxPt used.  
This result suggests that carnosine can interact with the OxPt drug forming complexes that 
reduce the drug’s action.   
In order to investigate the ability of carnosine to be passively diffused through cells, the same 
set of experiments were repeated but now cells were first incubated for 24 hours with 
carnosine at various concentrations.  After this incubation period, the media containing 
carnosine was discarded and fresh media containing 24 μg ml-1 of OxPt were added and 
allowed to incubate with the cells for a further 24 hour period.  The results of these last set of 
in vitro experiment shown in Figure 3 indicate slight increased cell viability upon the 
exposure to carnosine.  The much less pronounced effect shown in Figure 3 relative to that 
shown in Figure 2 is most likely due to the inability of carnosine to effectively passively 
diffuse through the cells.  This also suggests that the process is kinetically controlled and is 
consistent with the near constant cell viability data obtained whenever the carnosine was 
present irrespective of the concentration at which it was allowed to incubate with the cells.  
While no claim is made that the in vitro data presented here replicates biological conditions 
in which OxPt and carnosine might interact, they do however indicate that the dipeptide 
carnosine has the ability to interact with OxPt most likely through the chelation of the 
platinum metal and thus if such interaction were present it may reduce the cytotoxic action of 
OxPt and thus warrants the investigation of such complexes.   
To study the complexes of each of carnosine and its derivatives, anserine and N-acetyl-
carnosine with oxaliplatin experiments were performed on four different mass spectrometers 
as detailed in the Instrumentation section.   For the interest of conciseness, only selected 
representative results are shown here, however, all data are available in supplementary 
material.  All sample solutions employed in this work were a 2 : 1 mM mixtures of either 
carnosine, anserine or N-acetyl-carnosine with oxaliplatin in a 1 : 1 (v/v) water/methanol 
solutions. Electrosparying each of these three solutions in the positive ion mode generated the 
mass spectra shown in Figures 4-6 (also see Figures S1 and S2 in supplementary material).  
In all cases, irrespective of the instrument used, the base peaks obtained were due to [M + 
H]+ ions where M = carnosine, anserine or N-acetyl-carnosine.  These ions corresponded to 
the signals at m/z values of 227, 241 and 269 shown in Figures 4, 5 and 6 (also see Figures 
S1 and S2) respectively.  Three other common ions were observed in each of the full scan MS 
spectra of the three solution mixtures examined here.  Signals due to protonated oxaliplatin, 
[OxPt + H]+, were always present as evidenced by the clusters observed in all full scan MS 
spectra obtained at around m/z 398.  The lowest energy structure calculated for this 
protonated species was previously reported to have the external proton located on the ‘inside’ 
position of one of the oxalate carbonyl oxygen atoms. [21]  Protonated ligand dimers, [M2 + 
H]+ ions, were also observed at m/z 453, 481 and 537 as seen in Figures 4, 5 and 6 (also see 
Figures S1 and S2).  The third ion observed in all full scan MS spectra obtained was due to 
the [M + OxPt + H]+ species as seen in the clusters around m/z 624, 637 and 666 in Figures 4 
(also see Figure S1), 5 (also see Figure S2), and 6. 
The assignments of these ions were confirmed by comparing the observed isotopic patterns to 
those theoretically modelled for each of the proposed species.    For further confirmation the 
isotopic patterns for the proposed [Carnosine + OxPt + H]+ and [Anserine + OxPt + H]+ 
species being the focus of this study were obtained on the Q-Exactive FT-MS at a resolving 
power of about 60,000 and compared to their theoretical isotopic patterns at an equivalent 
resolution, the average error obtained over all the isotopic peaks observed were 2.13 and 1.48 
ppm for [Carnosine + OxPt + H]+ and [Anserine + OxPt + H]+ respectively.  This mass 
accuracy obtained without the use of lock masses provided unequivocal identifications as 
seen in Figures S3 and S4 of the supplementary material.   
The significantly lower signal intensities of the [OxPt + H]+ ion cluster centered at m/z 398 
relative to the [M + H]+ ions observed here as the base peaks in Figures 4-6 (also see Figures 
S1 and S2) was also observed previously where similar conditions were used but where M 
was glutathione. [21]  Several explanations were given for this observations including the 
difference in proton affinities of OxPt and M. [21]  The proton affinity of OxPt at 298 K was 
previously reported to be 233.5 kcal mol-1 [21] whereas the proton affinities for Carnosine, 
anserine and N-acetyl-carnosine is calculated here to be 254.4, 255.9 and 250.2 kcal mol-1  
respectively.  To the best of our knowledge the proton affinities of anserine and N-acetyl-
carnosine are the first reported values in the literature while three previously calculated 
values for the proton affinities of carnosine were given at 256.5 (at 0 K), [50] 245.4, [51] and 
232.98, [52] kcal mol-1. The latter of these values most likely needs to be revisited as it is 
significantly lower than all other calculated values and the only available experimental value 
for the proton affinity of carnosine of 244.59 kcal mol-1 obtained by the Graham Cooks 
method [51].  The proton affinities for Carnosine , anserine and N-acetyl-carnosine calculated 
here are in agreement with the lower [OxPt + H]+ signal intensity relative to each of their 
respective protonated [M + H]+ ions observed here.  
Figures 7-9 and S5 of the supplementary material show the MS2 spectra obtained by the mass 
selection followed by the subsequent fragmentation of each of the three [M + OxPt + H]+ 
species, where M= carnosine, anserine and N-acetyl-carnosine.  These spectra indicate 
common fragmentation pathways leading to the generation of several common ions being [M 
+ H]+, [OxPt + H]+, [M + OxPt – CO2 + H]+, [M – H + Pt(dach)]+ where M= carnosine, 
anserine and N-acetyl-carnosine; OxPt is oxaliplatin and dach is diaminocyclohexane as 
indicated earlier in the text.             
The precursor ion [Carnosine + OxPt + H]+ were theoretically examined in great detail in the 
gas phase and in solution as this complex is most likely formed initially in the solution 
mixture used here.  The potential energy surfaces of this complex in the gas phase and in 
solution were found to be relatively flat with several low lying minima as listed in Table 1 
and shown in Figures 10 and 11.  The calculated structures on these potential energy surfaces 
can be divided in two categories involving either direct Pt bonding to carnosine or 
electrostatic interactions between protonated carnosine and OxPt.  The bonding category 
involves the substitution of a single Pt-oxygen bond of the oxalate moiety of OxPt by a 
formal Pt-coordination to an electron rich site on the carnosine substrate; this typically being 
one of the imidazole nitrogen atoms, a carbonyl oxygen or the terminal amino nitrogen of the 
dipeptide as shown in Figure 11.  The electrostatic category on the other hand involves 
electrostatic interactions between the oxaliplatin molecule and protonated carnosine through 
hydrogen bonding which are responsible for keeping the resulting [Carnosine + OxPt + H]+ 
complex together as shown in Figure 11.  It is interesting to note that all the structures 
constituting this category involve the formal protonation of the carnosine ligand as opposed 
to OxPt.  This is consistent with the higher calculated proton affinity of carnosine relative to 
Oxpt as discussed earlier.  Structures in the first and latter of these categories calculated to be 
within about 15 kcal mol-1 in free energy of both the gas phase and solution global minina 
found are shown in Figures 10 and 11 respectively, while all structures calculated on this 
potential energy surface are listed in Table S1 in supplementary material. Seven of the eleven 
structures shown in Figure  involve Pt coordination to either the pros or tele nitrogen atoms 
of the histidine ring of carnosine.  Structures 1A, 1B and 1D in Figure 10, all resulting in the 
cluster centred on m/z 624 as seen in Figure 4 and Figures S1 and S3 of the supplementary 
material, comprise the two lowest energy conformers in the gas phase and the lowest two 
energy conformers in solution on these potential energy surfaces.  These three structures all 
involve Pt coordination to the pros nitrogen atoms of the histidine ring of carnosine and 
formal protonation on one of the carbonyl oxygen atoms of the oxalate moiety of oxaliplatin.  
This is consistent with an earlier study examining the silver ion binding energies of all 20 α-
amino acids, showing that histidine had the third highest silver ion binding energy being 
lower than that of arginine and only slightly lower than that of lysine. [53] The lowest energy 
conformer of the Ag+-histidine complex in that perious study also showed Pt-coordination to 
the pros nitrogen atoms of the histidine ring. [53] Here, the global minimum on the gas phase 
potential energy surface is structure 1A as shown in Figure 10, this structure is internally 
stabilised by four strong hydrogen bonds making it 3.4 kcal mol-1 lower in energy in the gas 
phase relative to 1D and only 0.8 kcal mol-1 removed from the lowest energy structure 
calculated on the solution phase potential energy surface being structure 1D as shown in 
Figure 10.  Structure 1D is also stabilised by two internal hydrogen bonds.  It is interesting to 
note that in the gas phase structure 1A the hydrogen bond between one of the NH hydrogen 
atoms of the dach ligand and the carboxylic oxygen of the terminal carboxylate group being 
at 1.886 Å becomes none existent in solution (distance of 5.297 Å as shown in Figure 10) as 
it is replaced by external solvation.  The strongest hydrogen bonds in either the two gas phase 
structures, 1A and 1D, is between each of the hydrogen atoms of the protonated oxalate 
moieties and their respective terminal amino nitrogen atom of each of the carnosine 
dipeptides.  This is determined based on the shortest hydrogen bonding distance calculated in 
either gas phase structure being 1.315 and 1.328 Å for structures 1A and 1D respectively as 
well as on the resulting hydrogen bonding angles being closest to the ideal linear arrangement 
calculated to be 166º for the N-H-O in both cases.  
In the solution phase on the other hand structures 1A and 1D both have their terminal amino 
nitrogen atoms protonated while forming strong hydrogen bonds to a carboxylic oxygen atom 
of the oxalate moiety in each case at 1.509 and 1.496 Å respectively.   If the solution phase 
structures 1A or 1D being the two lowest energy structures on that potential energy surface 
are transferred to the gas phase by solvent evaporation through the soft electrospray 
ionisation technique while maintaining the protonation on the terminal amino nitrogen atom a 
structure 1K or 1I would result, this structure is similar to 1C with the noted difference that 
structure 1C involves Pt coordination to the tele nitrogen of the histidine ring.  Structure 1K 
is calculated to be energetically competitive in the gas phase and in solution being only 8.7 
and 2.7 kcal mol-1 removed from either global minina respectively.   Alternatively, the gas-
phase transfer of the hydrogen atom of the protonated oxalate moiety to the terminal amino 
nitrogen atom in either gas phase structure 1A or 1D while maintaining the Pt coordination to 
the pros nitrogen of histidine would also results in the formation of structure 1K or 1I.   The 
loss of CO2 from the deprotonated oxalate moiety of this resulting structure, 1K or 1I, 
followed by a proton transfer from the formally protonated NH3+ group of the carnosine 
dipeptide to the carbon atom of the remaining CO2 group of the oxalate moiety of results in 
the formation of structure 2A shown in Figure 12.  Structure 2A is the lowest energy structure 
calculated for the [Carnosine + OxPt – CO2 + H]+ species observed as the m/z cluster around 
580 in the MS2 spectra shown in Figure 4 and as the signals at m/z 579, 580 and 581 for 194Pt, 
195Pt and 196Pt  as shown in panels A, B and C of Figure S5 respectively.  Structure 2A is 
shown to contain three internal hydrogen bonds which help stabilise it.  It is interesting to 
note that the lowest three energy structures calculated for the [Carnosine + OxPt – CO2 + H]+ 
species, assigned as the cluster centred on m/z 580 as seen in Figure 7 and resulting in the 
signals at m/z 579, 580 and 581 in panels A, B and C respectively of Figure S5 of the 
supplementary material also all involve Pt-coordination to the Pros nitrogen atom of the 
hystidine ring of the carnosine dipeptide.   Structures 2B and 2C are calculated to be only 2.6 
and 5.9 kcal mol-1 higher in free energy relative to structure 2A respectively.  The gas phase 
inter-conversion between these three structures is expected to be rapid and well within the 
energies available under the collision induced dissociation conditions employed here as they 
involve simple rotations about single bonds.  Interestingly, structure 2C involves a hydrogen 
bond at 1.765 Å between the OH hydrogen of the carboxylate group of the carnosine 
dipeptide and the Pt-bound oxygen atom of the remaining HCO2 group of the oxalate moiety.  
The transfer of this hydrogen atom from the OH group to the carboxylate group of carnosine 
followed by the neutral loss of the resulting H2CO2 group and the subsequent binding of the 
resulting carboxylic oxygen to the Pt center results in structure 3A shown in Figure 13.  
Structure 3A is calculated to be the lowest structure for the [Carnosine – H + Pt(dach)]+ 
species assigned as the cluster centered on mz/534 in Figure 7 and the signals at m/z 533, 534 
and 535 in panels A, B and D respectively in Figure S5 of the supplementary material. This 
assignment was further confirmed by the isotopic pattern obtained on the high resolution Q-
Exactive FT-MS shown in Figure S6 of the supplementary material.  The formation of the 
[Carnosine – H + Pt(dach)]+ species from the [Carnosine + OxPt – CO2 + H]+ precursor is 
supported by the MS3 spectrum in Figure S7 clearly showing the cluster centred on m/z 534 
being the dominant fragment due to the dissociation the[Carnosine + OxPt – CO2 + H]+ 
precursor.   
The two other signals observed at significantly lower intensities in Figure S7 are the clusters 
centred on m/z 517 and 354.  These signals were also weak signals observed in the MS2 
spectrum of [Carnosine + OxPt + H]+ shown in Figures 7 and S5 of the supplementary 
material and were assigned as [Carnosine – NH3 – H + Pt(dach)]+ and [OxPt – CO2 + H]+ 
respectively.  The latter of these species is most likely produced via the neutral loss of 
carnosine from [Carnosine + OxPt – CO2 + H]+ species clustered on m/z 580 generating the 
ion [OxPt – CO2 + H]+, Structures 5A and 5B in Table 1.  The lowest energy of these two 
structures contains a Pt centre that is dicoordinated to the dach ligand while forming two 
other symmetrical bonds to either oxygen atom of the COOH moiety.   
The species observed as a cluster centred on m/z 517 assigned as [Carnosine – NH3 – H + 
Pt(dach)]+ is most likely due to the loss of NH3 from [Carnosine – H + Pt(dach)]+ as 
confirmed by MS4 data (not shown).  Here, a 1,3 hydride shift to the terminal amino nitrogen 
atom of the lowest energy species on the [Carnosine – H + Pt(dach)]+ surface, Structure 3A, 
and the subsequent loss of the resulting NH3 group results in the formation of the lowest 
energy structure calculated for the [Carnosine – NH3 – H + Pt(dach)]+ species, structure 4A, 
being the lowest energy species on this surface as shown in Figure 14.   
Conclusions 
In this paper, in vitro studies on hepatocellular carcinoma HepG2 cells suggest that the 
dipeptide carnosine may inhibit the cytotoxic action of OxPt most likely through the 
formation of complexes that are less cytotoxic than OxPt alone.  Evidence was provided to 
suggest that pre-exposure of HepG2 cells to elevated levels of carnosine appears to have a 
lasting effect on reducing the cytotoxicity of OxPt even after the removal of the carnosine.  
This effect, however, was shown to be under kinetic control as its magnitude was shown not 
to vary significantly with the level of carnosine exposure within the concentration range used 
in this study.   Various mass spectrometry techniques employing electrospray ionization and 
chip nanospray were employed to study the interaction of oxaliplatin with the naturally 
abundant cytoplasmic dipeptide ligand β-alanyl-L-histidine (carnosine) as well as two of its 
derivatives being β-alanyl-N-methylhistidine (anserine) and N-Acetylcarnosine (NAC).  
Evidence of complexation between OxPt and each of the three ligands examined is presented.  
Most species observed were unambiguously assigned and compared to their theoretical 
isotopic patterns.  Common fragmentation products due to the collisionally-activated 
protonated complexes of each of the ligands examined with OxPt, [M + OxPt + H]+ where 
M= carnosine, anserine or NAC were shown to be [OxPt – CO2 + H]+, [OxPt + H]+, [M – H 
+ Pt(dach)]+, [M + OxPt – CO2 + H]+ and [M +H]+.  Density functional calculations at 
B3LYP/LANL2DZ were used to obtain structural information and relative free energies of 
different isomers of the observed precursor [Carnosine + OxPt + H]+ and the fragments 
produced  highlighting plausible fragmentation mechanisms that account for all the 
experimental results.  Data presented showed several binding modes between electron rich 
sites such as N and O centers of Carnosine and the Pt metal of OxPt.  Values for proton 
affinities of carnosine, anserine and NAC at 298 K were calculated to be 254.4, 255.9 and 
250.2 kcal mol-1 respectively.    
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Figure 1.  Percent viability of HepG2 cells upon exposure to varying concentrations of Oxaliplatin for 24 hours.  Each data point within 
an experiment is the average of three separate runs.  The data presented here in boxplot format are the average of three separate 
experiments.  Error bars represent the Standard error of deviation and the statistical significance is represented by * for P <0.01, ** for 
P <0.0001 and *** for P < 0.00001 
*** 
*** *** 
*** 
Figure 2. Percent viability of HepG2 cells upon exposure to increasing molar ratios of carnosine in the presence of 24μg ml-1 oxaliplatin for 
24 hours. Values at (0:1, 1:1, 1.5:1, 2:1 and 2.5:1) refer to the molar ratios of carnosine to oxaliplatin. Each data point within an experiment is 
the average of three separate runs.  The data presented here in boxplot format are the average of three separate experiments. Error bars 
represent the Standard error of deviation and the statistical significance of the solution mixtures relative to 24 ug/ml Oxaliplatin is represented 
by * for P<0.001, ** for P <0.0001 and *** for P <0.00001 
*** *** *** *** *** 
Figure 3. Percent viability of HepG2 cells upon the initial exposure to increasing carnosine concentrations followed by the exposure to 
24μg ml-1 oxaliplatin for 24 hours. Values at (0.5:1, 1:1, 1.5:1, 2:1 and 2.5:1) refer to the molar ratios of carnosine to oxaliplatin. Each data 
point within an experiment is the average of three separate runs.  The data presented here in boxplot format are the average of three 
separate experiments.  Error bars represent the Standard error of deviation. 
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Figure 4: Full scan MS spectrum of a (2:1) molar mixture of Carnosine and OxPt in a (1:1) (v/v) water/methanol solution as obtained on 
the LTQ without allowing for incubation time.  The sections of the spectrum shown under “x10” signify the magnification of the signal by 
10 fold for clarity.  This magnification means that for example the intensity of the ion at m/z 453.0 is about 3% of the base peak.  The 
signals assigned as [OxPt + H]+ and [Carnosine + OxPt + H]+ are each expanded and normalized to 100% in inserts A and B respectively 
for clarity. 
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Figure 5: Full scan MS spectrum of a (2:1) molar mixture of Anserine and OxPt in a (1:1) (v/v) water/methanol solution as obtained on 
the LTQ without allowing for incubation time.  The sections of the spectrum shown under “x10” signify the magnification of the signal by 
10 fold for clarity.  This magnification means that for example the intensity of the ion at m/z 481.0 is about 2% of the base peak.  The 
signals assigned as [OxPt + H]+ and [Anserine + OxPt + H]+ are each expanded and normalized to 100% in inserts A and B respectively 
for clarity. 
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obtained on the Acquity TQ without allowing for incubation time. The signals assigned as [OxPt + H]+ and [N-acetyl-carnosine + OxPt + 
H]+ are each expanded and normalized to 100% in inserts A and B respectively for clarity. 
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Figure 7: MS2 spectrum of the entire isotopic envelope of the ion [Carnosine + OxPt + H]+ generated at 15 ev in the lab frame and 
isolated from the full scan spectrum of a (2:1) molar mixture of Carnosine and OxPt in a (1:1) (v/v) water/methanol solution as obtained 
on the LTQ without allowing for incubation time.  The sections of the spectrum shown under “x10” and “x50” signify the magnification 
of the signal by 10 and 50 fold respectively for clarity. The signals assigned as [OxPt – CO2 + H]+, [OxPt + H]+, [Carnosine – H + 
Pt(dach)]+ and [Carnosine + OxPt – CO2 + H]+ are each expanded and normalized to 100% in inserts A through D respectively for clarity. 
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Figure 8: MS2 spectrum of the entire isotopic envelope of the ion [Anserine + OxPt + H]+ generated at 25 eV in the lab frame and isolated 
from the full scan spectrum of a (2:1) molar mixture of Anserine and OxPt in a (1:1) (v/v) water/methanol solution as obtained on the 
LTQ without allowing for incubation time.  The sections of the spectrum shown under “x50” signify the magnification of the signal by 50 
fold for clarity. The signals assigned as [OxPt – CO2 + H]+, [OxPt + H]+, [Anserine – H + Pt(dach)]+ and [Anserine + OxPt – CO2 + H]+ 
are each expanded and normalized to 100% in inserts A through D respectively for clarity. 
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Figure 9: MS2 spectrum of the ion [N-acetyl-carnosine + OxPt + H]+ generated at 20 eV in the lab frame and isolated from the full scan 
spectrum of a (2:1) molar mixture of N-acetyl-carnosine (NAC in this Figure) and OxPt in a (1:1) (v/v) water/methanol solution as 
obtained on the Acquity TQ without allowing for incubation time. Panels A, B and C show the CID patterns obtained due to the isotopes 
194Pt, 195Pt and 196Pt  of [N-acetyl-carnosine + OxPt + H]+ respectively. 
A 
B 
C 
[NAC + Ox194Pt – CO2 + H]+ 
[NAC – H + 194Pt(dach)]+ 
[Ox194Pt + H]+ 
[Ox194Pt – CO2 + H]+ 
[Ox195Pt – CO2 + H]+ 
[Ox196Pt – CO2 + H]+ 
[Ox195Pt + H]+ 
[Ox196Pt + H]+ 
[NAC + H]+ 
[NAC + H]+ 
[NAC + H]+ 
[NAC – H + Pt195(dach)]+ 
[NAC – H + Pt196(dach)]+ 
[NAC + Ox195Pt – CO2 + H]+ 
[NAC + Ox196Pt – CO2 + H]+ 
[NAC + Ox194Pt + H]+ 
[NAC + Ox195Pt + H]+ 
[NAC + Ox196Pt + H]+ 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.859 
1.954 
2.066 
2.056 2.056 
2.067 
2.051 
2.076 
2.071 
2.070 
1.569 
1.634 
1A (0.0, 0.8) 
1B (0.4, 8.5) 
1C (2.7, 7.6) 
1D (3.4, 0.0) 
1E (5.4, 2.6) 
1F (5.9, 15.6) 
1.504 
1.506 
1.040 
1.040 
1.886 
5.297 
2.088 
2.075 
2.066 
2.050 
2.069 
2.070 
2.073 
2.080 1.814 2.020 
1.184 
1.509 
1.315 
1.094 
1.317 
1.540 
2.074 
2.070 
2.045 
2.049 
2.084 
2.085 
2.064 
2.078 
1.758 
1.751 
1.173 
1.496 
1.328 
1.100 
2.041 
2.064 
2.092 
2.074 
2.081 
2.081 
2.052 
2.047 
1.814 
1.972 
1.684 
1.776 
1.459 
1.624 
2.075 
2.076 
2.051 
2.080 
2.095 
2.076 2.054 
2.044 
1.819 
1.964 1.754 
1.767 
1.368 
1.531 
1.141 
1.077 
2.031 
2.066 
2.109 
2.083 
2.118 
2.118 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.275 
1.500 1.218 
1.098 
1.725 
1.802 
2.040 
2.047 
2.036 
2.065 
2.082 
2.083 
2.102 
2.075 
1.293 
1.507 
1.605 
1.472 2.079 
2.087 
2.082 
2.069 
2.068 
2.079 
2.047 
2.045 
1.083 
1.454 
1.482 
1.117 
1.813 
1.906 
1.611 
1.767 
2.033 
2.070 
2.063 
2.066 
2.077 
2.066 
2.059 
2.075 
1G (6.5, 7.3) 
1H (6.7, 14.9) 
1I (6.7, 4.5) 
1J (7.4, 6.3) 
1K (8.7, 2.7) 
Figure 10: Structures for [Carnosine + OxPt + H]
+
 ions in which a formal Pt coordination to carnosine is observed 
as calculated at the B3LYP/LANL2DZ level of theory.  Bond lengths are in Angstroms, relative free energies are 
indicated in parenthesis. Italicized numbers are for solvated species. 
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Figure 11: Structures for [Carnosine + OxPt + H]
+
 ions in which no formal Pt coordination to carnosine is observed 
as calculated at the B3LYP/LANL2DZ level of theory.  Bond lengths are in Angstroms, relative free energies are 
indicated in parenthesis. Italicized numbers are for solvated species. 
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+
 ions as calculated at the B3LYP/LANL2DZ level of 
theory.  Bond lengths are in Angstroms, relative free energies are indicated in parenthesis.  
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 ions as calculated at the B3LYP/LANL2DZ level of theory.  
Bond lengths are in Angstroms, relative free energies are indicated in parenthesis.  
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Figure 14: Structures for [Carnosine – NH3 – H + Pt(dach)]
+
 ions as calculated at the B3LYP/LANL2DZ level of 
theory.  Bond lengths are in Angstroms, relative free energies are indicated in parenthesis.  
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Figure S1: Full scan MS spectrum of a (2:1) molar mixture of Carnosine and OxPt in a (1:1) (v/v) water/methanol solution as obtained on 
the Acquity TQ without allowing for incubation time. The signals assigned as [OxPt + H]+ and [Carnosine + OxPt + H]+ are each 
expanded and normalized to 100% in inserts A and B respectively for clarity. 
Figure S2: Full scan MS spectrum of a (2:1) molar mixture of Anserine and OxPt in a (1:1) (v/v) water/methanol solution as obtained on 
the XEVO TQ without allowing for incubation time.  The section of the spectrum shown under “x10” signify the magnification of the 
signal by 10 fold for clarity.  This magnification means that for example the intensity of the ion at m/z 637.2 is about 4% of the base peak. 
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Figure S3: Full scan MS spectrum of a (2:1) molar mixture of Carnosine and OxPt in a (1:1) (v/v) water/methanol solution as obtained on 
the Q-Exactive FT-MS without allowing for incubation time showing the isotopic pattern of [Carnosine + OxPt +H]+.  The sections of the 
spectrum shown under “x5” signify the magnification of the signal by 5 fold for clarity. Panel A shows the experimental data wile Panel B 
shows the theoretically modeled spectrum using the Thermo Xcalibur software.  Errors in ppm are listed next to each of the experimental 
isotopic peaks observed. 
Figure S4: Full scan MS spectrum of a (2:1) molar mixture of Anserine and OxPt in a (1:1) (v/v) water/methanol solution as obtained on 
the Q-Exactive FT-MS without allowing for incubation time showing the isotopic pattern of [Anserine + OxPt +H]+.  The sections of the 
spectrum shown under “x10” signify the magnification of the signal by 10 fold for clarity. Panel A shows the experimental data wile Panel 
B shows the theoretically modeled spectrum using the Thermo Xcalibur software.  Errors in ppm are listed next to each of the 
experimental isotopic peaks observed. 
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Figure S5: MS2 spectrum of the ion [Carnosine + OxPt + H]+ generated at 25 eV in the lab frame and isolated from the full scan spectrum 
of a (2:1) molar mixture of Carnosine and OxPt in a (1:1) (v/v) water/methanol solution as obtained on the Acquity TQ without allowing 
for incubation time. Panels A, B and C show the CID patterns obtained due to the isotopes 194Pt, 195Pt and 196Pt  of [Carnosine + OxPt + 
H]+ respectively. 
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Figure S6: Tandum mass spectra of a (2:1) molar mixture of Carnosine and OxPt in a (1:1) (v/v) water/methanol solution as obtained on the 
Q-Exactive FT-MS without allowing for incubation time showing the isotopic pattern of [Carnosine – H + Pt(dach)]+.  Panel A shows the 
experimental data wile Panel B shows the theoretically modeled spectrum using the Thermo Xcalibur software.  Errors in ppm are listed 
next to each of the experimental isotopic peaks observed. Errors in ppm are listed next to each of the experimental isotopic peaks observed. 
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Figure S7: Tandem mass spectra of the fragment ion cluster centered around m/z 580 generated and isolated from the CID of [Carnosine + 
OxPt + H]+ at 30 eV in the lab frame which is in turn isolated from the full scan spectrum of a (2:1) molar mixture of Carnosine and OxPt 
in a (1:1) (v/v) water/methanol solution as obtained on the LTQ. 
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Table S1: Electronic energies, Zero-Point Vibrational Energies, Thermal Energies, Entropies 
and relative free energies for species calculated at B3LYP\LANL2DZ.  Italicized values are 
for PCM calculations in a water solvent.  Structures 1A-1U refer to [Carnosine + OxPt + H]+ 
in which direct Pt bonding to carnosine is observed.  Structures 1V-1Y refer to [Carnosine + 
OxPt + H]+ in which no direct Pt bonding to carnosine is observed. Structures 2A-2N, 3A-
3G, 4A-4M and 5A-5B refer to [Carnosine + OxPt – CO2 + H]+, [Carnosine – H + 
Pt(dach)]+, [Carnosine – NH3 – H + Pt(dach)]+ and [OxPt – CO2 + H]+ respectively. 
Structure 
 
Electronic 
energy 
(Hartrees) 
ZPE 
(kcal mol-1) 
𝐇𝟐𝟗𝟖
𝐨 − 𝐇𝟎
𝐨 
(kcal mol-1) 
Entropy 
(cal mol-1 K-1) 
Relative free 
energy at 298 K 
(kcal mol-1) 
1A -1639.2886242 312.6 19.6 196.8 0.0 
 -1639.4050202 314.6 19.9 201.1 0.8 
1B -1639.2858222 312.8 20.0 203.4 0.4 
 -1639.3913698 314.5 20.1 204.5 8.5 
1C -1639.2867573 314.4 19.6 197.5 2.7 
 -1639.3956112 315.2 19.8 200.1 7.6 
1D -1639.2796868 312.7 20.0 205.4 3.4 
 -1639.4041530 314.2 20.0 204.7 0.0 
1E -1639.2784107 313.5 19.8 203.6 5.4 
 -1639.4015638 314.5 19.7 201.5 2.6 
1F -1639.2732867 312.9 20.7 213.8 5.9 
 -1639.3731196 312.8 20.8 215.6 15.6 
1G -1639.2758092 312.9 20.1 204.4 6.5 
 -1639.3914762 314.0 20.3 207.1 7.3 
1H -1639.2729851 312.2 20.1 207.4 6.7 
 -1639.3770276 314.2 20.5 213.3 14.9 
1I -1639.2778140 312.9 19.7 198.0 6.7 
 -1639.3970803 313.9 20.1 203.7 4.5 
1J -1639.2760210 313.7 19.8 202.3 7.4 
 -1639.3961354 314.9 19.9 202.4 6.3 
1K -1639.2716859 312.5 20.2 204.9 8.7 
 -1639.3958654 314.3 20.3 214.4 2.7 
1L -1639.2723656 312.9 20.3 206.1 8.3 
 -1639.3651803 312.2 20.3 207.8 21.9 
1M -1639.2680874 312.9 20.4 210.2 9.9 
 -1639.3712658 312.5 20.5 212.7 17.0 
1N -1639.2702447 314.2 20.1 202.5 11.8 
 -1639.3699854 314.1 20.3 206.5 21.1 
1O -1639.2751572 314.9 19.4 192.0 11.9 
 -1639.3845742 313.7 19.7 197.0 13.7 
1P -1639.2677622 313.4 20.2 204.1 12.2 
 -1639.3703845 313.5 20.4 205.0 20.8 
1Q -1639.2640107 313.8 19.6 200.3 15.5 
 -1639.3799232 313.8 19.9 204.8 14.6 
1R -1639.2631978 313.4 20.0 201.1 15.8 
 -1639.3842329 315.0 20.3 208.0 12.6 
1S -1639.2554539 314.0 20.2 207.2 19.6 
 -1639.3634689 313.5 20.3 209.7 23.6 
1T -1639.2554538 314.0 20.2 207.2 19.6 
 -1639.3634688 313.5 20.3 209.7 23.6 
1U -1639.2500998 312.1 20.6 212.9 19.8 
 -1639.3468289 311.9 20.7 214.6 31.4 
1V -1639.2855972 313.4 20.1 204.5 0.8 
 -1639.3803957 313.2 20.4 208.5 13.1 
1W -1639.2750738 312.9 20.7 216.3 4.0 
 -1639.3730479 312.7 20.8 217.2 15.2 
1X -1639.2806661 313.8 20.0 202.2 5.0 
 -1639.3792743 313.5 20.3 206.4 14.8 
1Y -1639.2698582 313.8 20.6 219.8 7.1 
 -1639.3745151 314.0 20.7 218.0 15.1 
2A -1450.7542132 304.6 18.5 192.5 0.0 
2B -1450.7521575 304.7 18.1 187.2 2.6 
2C -1450.7488908 305.0 18.2 184.3 5.9 
2D -1450.7396653 304.6 18.2 186.7 10.5 
2E -1450.7359210 304.2 18.4 189.4 11.9 
2F -1450.7356931 304.0 18.2 186.5 12.5 
2G -1450.7278354 303.5 18.6 198.1 13.9 
2H -1450.7225517 305.3 18.3 190.2 21.0 
2I -1450.7156471 305.4 18.5 193.8 24.6 
2J -1450.6987011 302.4 18.6 191.6 33.0 
2K -1450.6951026 303.3 18.8 199.0 34.1 
2L -1450.6961826 302.4 18.3 188.4 35.3 
2M -1450.6910914 302.8 18.4 189.3 38.6 
2N -1450.6692231 302.7 19.0 199.4 49.9 
3A -1260.9744123 282.5 15.8 168.1 0.0 
3B -1260.9646407 281.5 16.4 174.2 3.9 
3C -1260.9499510 283.0 15.7 171.6 14.8 
3D -1260.9471698 282.5 15.6 164.1 18.1 
3E -1260.9382042 283.1 15.3 159.5 25.4 
3F -1260.8792520 280.7 16.1 171.0 57.3 
3G -1260.8353995 281.2 15.5 163.5 86.9 
4A -1204.3891678 256.0 15.1 162.6 0.0 
4B -1204.3888797 256.2 14.7 157.3 1.6 
4C -1204.3795752 255.7 15.1 164.3 5.2 
4D -1204.3716679 255.2 15.1 166.1 9.3 
4E -1204.3753032 256.7 14.6 159.2 10.0 
4F -1204.3612046 255.2 14.9 161.7 16.8 
4G -1204.3318604 255.0 14.9 162.3 34.9 
4H -1204.3247413 254.8 15.1 166.2 38.2 
4I -1204.3241914 255.0 15.0 163.8 39.4 
4J -1204.3113922 254.7 14.8 158.9 48.4 
4K -1204.2953955 255.0 14.7 158.5 58.8 
4L -1204.2460587 253.0 15.6 169.7 85.3 
4M -1204.2346476 252.8 15.7 166.6 93.2 
5A -654.6722639 148.4 8.1 109.6 0.0 
5B -654.6344513 145.8 9.0 121.9 18.4 
 
